Iovance Biotherapeutics (IOVA) announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6th, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics downgraded to Sell from Neutral at Goldman Sachs
- H.C. Wainwright sees ‘impressive’ commercial data for Iovance’s Amtagvi
- Iovance Biotherapeutics announces real-world study data on Amtagvi
- Iovance Biotherapeutics Advances Phase 3 Study in Melanoma Treatment
- Iovance Biotherapeutics’ Lifileucel-Pembrolizumab Study: A Potential Game-Changer in Melanoma Treatment